ScripThe latest readout of data from Regenxbio’s Phase I/II AFFINITY DUCHENNE study of its gene therapy RGX-202 in Duchenne muscular dystrophy (DMD) offers more support for the firm’s plan to seek US Food
ScripBiopharmaceutical companies raised just $13.1bn during the first quarter of 2025 – less than half of the $30.1bn raised in Q1 of 2024, the latest Financing Quarterly Statistics report from Biomedtra
Pink SheetThe regenerative medicine sector continues to seek increased contact with the US Food and Drug Administration, even as the architects of the Center for Biologics Evaluation and Research review structu
ScripNews that US Food and Drug Administration Center for Biologics Evaluation and Research (CBER) director Peter Marks submitted his resignation, effective 5 April, late in the day on 28 March shook the b